nodes	percent_of_prediction	percent_of_DWPC	metapath
Dinoprostone—SLCO3A1—Methotrexate—muscle cancer	0.212	0.273	CbGbCtD
Dinoprostone—SLCO1C1—Methotrexate—muscle cancer	0.136	0.175	CbGbCtD
Dinoprostone—SLC22A11—Methotrexate—muscle cancer	0.07	0.0902	CbGbCtD
Dinoprostone—SLC22A7—Methotrexate—muscle cancer	0.0667	0.0859	CbGbCtD
Dinoprostone—ABCC4—Methotrexate—muscle cancer	0.0652	0.084	CbGbCtD
Dinoprostone—SLCO1A2—Methotrexate—muscle cancer	0.0468	0.0602	CbGbCtD
Dinoprostone—CYP1A2—Dacarbazine—muscle cancer	0.0447	0.0576	CbGbCtD
Dinoprostone—SLCO1B1—Methotrexate—muscle cancer	0.0441	0.0568	CbGbCtD
Dinoprostone—SLC22A8—Methotrexate—muscle cancer	0.0407	0.0525	CbGbCtD
Dinoprostone—SLC22A6—Methotrexate—muscle cancer	0.0284	0.0365	CbGbCtD
Dinoprostone—CYP1A2—Etoposide—muscle cancer	0.0219	0.0282	CbGbCtD
Dinoprostone—SLC51B—tendon—muscle cancer	0.00327	0.0248	CbGeAlD
Dinoprostone—PTGER4—smooth muscle tissue—muscle cancer	0.00317	0.0241	CbGeAlD
Dinoprostone—PTGER4—renal system—muscle cancer	0.00305	0.0232	CbGeAlD
Dinoprostone—PTGER4—Small Ligand GPCRs—CNR1—muscle cancer	0.00299	0.0752	CbGpPWpGaD
Dinoprostone—HPGDS—embryo—muscle cancer	0.00295	0.0224	CbGeAlD
Dinoprostone—PTGER1—renal system—muscle cancer	0.00295	0.0224	CbGeAlD
Dinoprostone—Oedema genital—Doxorubicin—muscle cancer	0.00294	0.0579	CcSEcCtD
Dinoprostone—SLC51B—testis—muscle cancer	0.00271	0.0205	CbGeAlD
Dinoprostone—PTGER3—smooth muscle tissue—muscle cancer	0.00269	0.0204	CbGeAlD
Dinoprostone—PTGER3—renal system—muscle cancer	0.00259	0.0196	CbGeAlD
Dinoprostone—PTGER2—Small Ligand GPCRs—CNR1—muscle cancer	0.00245	0.0617	CbGpPWpGaD
Dinoprostone—PTGER2—tendon—muscle cancer	0.00243	0.0184	CbGeAlD
Dinoprostone—PTGER4—tendon—muscle cancer	0.00238	0.0181	CbGeAlD
Dinoprostone—PTGER2—bone marrow—muscle cancer	0.00235	0.0178	CbGeAlD
Dinoprostone—SLC51A—tendon—muscle cancer	0.00234	0.0178	CbGeAlD
Dinoprostone—PTGER3—Small Ligand GPCRs—CNR1—muscle cancer	0.00226	0.057	CbGpPWpGaD
Dinoprostone—PTGER2—vagina—muscle cancer	0.00225	0.0171	CbGeAlD
Dinoprostone—HPGDS—renal system—muscle cancer	0.00223	0.017	CbGeAlD
Dinoprostone—SLC51A—vagina—muscle cancer	0.00217	0.0165	CbGeAlD
Dinoprostone—PTGFR—smooth muscle tissue—muscle cancer	0.00215	0.0163	CbGeAlD
Dinoprostone—PTGER4—head—muscle cancer	0.00204	0.0155	CbGeAlD
Dinoprostone—PTGER2—testis—muscle cancer	0.00201	0.0153	CbGeAlD
Dinoprostone—SLC51A—head—muscle cancer	0.00201	0.0152	CbGeAlD
Dinoprostone—PTGER4—testis—muscle cancer	0.00197	0.015	CbGeAlD
Dinoprostone—PTGER1—head—muscle cancer	0.00197	0.015	CbGeAlD
Dinoprostone—SLC51A—testis—muscle cancer	0.00194	0.0147	CbGeAlD
Dinoprostone—PTGIR—smooth muscle tissue—muscle cancer	0.00189	0.0144	CbGeAlD
Dinoprostone—SLCO1C1—renal system—muscle cancer	0.00183	0.0139	CbGeAlD
Dinoprostone—PTGIR—renal system—muscle cancer	0.00182	0.0138	CbGeAlD
Dinoprostone—SLC22A11—renal system—muscle cancer	0.00178	0.0135	CbGeAlD
Dinoprostone—HPGDS—tendon—muscle cancer	0.00174	0.0132	CbGeAlD
Dinoprostone—SLC22A7—renal system—muscle cancer	0.00173	0.0131	CbGeAlD
Dinoprostone—PTGER3—head—muscle cancer	0.00173	0.0131	CbGeAlD
Dinoprostone—PTGFR—Small Ligand GPCRs—CNR1—muscle cancer	0.00169	0.0426	CbGpPWpGaD
Dinoprostone—HPGDS—bone marrow—muscle cancer	0.00169	0.0128	CbGeAlD
Dinoprostone—PTGER3—testis—muscle cancer	0.00167	0.0127	CbGeAlD
Dinoprostone—PTGIR—Small Ligand GPCRs—CNR1—muscle cancer	0.00166	0.0417	CbGpPWpGaD
Dinoprostone—PTGER1—Small Ligand GPCRs—CNR1—muscle cancer	0.00166	0.0417	CbGpPWpGaD
Dinoprostone—HPGDS—vagina—muscle cancer	0.00162	0.0123	CbGeAlD
Dinoprostone—PTGFR—tendon—muscle cancer	0.00161	0.0122	CbGeAlD
Dinoprostone—SLCO3A1—renal system—muscle cancer	0.00161	0.0122	CbGeAlD
Dinoprostone—SLCO2A1—renal system—muscle cancer	0.00159	0.0121	CbGeAlD
Dinoprostone—SLC22A2—renal system—muscle cancer	0.00154	0.0117	CbGeAlD
Dinoprostone—HPGDS—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—muscle cancer	0.00153	0.0385	CbGpPWpGaD
Dinoprostone—HPGDS—head—muscle cancer	0.0015	0.0113	CbGeAlD
Dinoprostone—SLCO4A1—renal system—muscle cancer	0.00146	0.0111	CbGeAlD
Dinoprostone—HPGDS—testis—muscle cancer	0.00144	0.011	CbGeAlD
Dinoprostone—SLCO3A1—cardiac atrium—muscle cancer	0.00144	0.0109	CbGeAlD
Dinoprostone—SLCO2A1—cardiac atrium—muscle cancer	0.00143	0.0108	CbGeAlD
Dinoprostone—PTGFR—head—muscle cancer	0.00138	0.0105	CbGeAlD
Dinoprostone—Dihomo-gamma-linolenic acid—PTGS2—muscle cancer	0.00136	1	CrCbGaD
Dinoprostone—PTGFR—testis—muscle cancer	0.00134	0.0101	CbGeAlD
Dinoprostone—SLCO4A1—cardiac atrium—muscle cancer	0.00131	0.00995	CbGeAlD
Dinoprostone—ABCC5—cardiac atrium—muscle cancer	0.0013	0.0099	CbGeAlD
Dinoprostone—SLCO1B1—renal system—muscle cancer	0.00129	0.00978	CbGeAlD
Dinoprostone—SLCO3A1—tendon—muscle cancer	0.00126	0.00952	CbGeAlD
Dinoprostone—SLCO2A1—tendon—muscle cancer	0.00124	0.00943	CbGeAlD
Dinoprostone—SLCO1C1—head—muscle cancer	0.00122	0.00928	CbGeAlD
Dinoprostone—PTGIR—head—muscle cancer	0.00122	0.00925	CbGeAlD
Dinoprostone—SLCO1C1—testis—muscle cancer	0.00118	0.00896	CbGeAlD
Dinoprostone—PTGIR—testis—muscle cancer	0.00118	0.00893	CbGeAlD
Dinoprostone—SLCO3A1—vagina—muscle cancer	0.00116	0.00884	CbGeAlD
Dinoprostone—SLCO2A1—vagina—muscle cancer	0.00115	0.00875	CbGeAlD
Dinoprostone—SLCO2B1—renal system—muscle cancer	0.00114	0.00865	CbGeAlD
Dinoprostone—ABCC5—tendon—muscle cancer	0.00114	0.00863	CbGeAlD
Dinoprostone—SLC22A7—testis—muscle cancer	0.00112	0.0085	CbGeAlD
Dinoprostone—ABCC5—bone marrow—muscle cancer	0.0011	0.00836	CbGeAlD
Dinoprostone—SLC22A1—renal system—muscle cancer	0.00109	0.00827	CbGeAlD
Dinoprostone—SLCO3A1—head—muscle cancer	0.00108	0.00816	CbGeAlD
Dinoprostone—SLCO2A1—head—muscle cancer	0.00107	0.00808	CbGeAlD
Dinoprostone—SLCO4A1—vagina—muscle cancer	0.00106	0.00805	CbGeAlD
Dinoprostone—ABCC5—vagina—muscle cancer	0.00105	0.008	CbGeAlD
Dinoprostone—CYP11A1—head—muscle cancer	0.00105	0.008	CbGeAlD
Dinoprostone—SLCO1A2—renal system—muscle cancer	0.00105	0.00796	CbGeAlD
Dinoprostone—SLCO3A1—testis—muscle cancer	0.00104	0.00789	CbGeAlD
Dinoprostone—SLCO2A1—testis—muscle cancer	0.00103	0.00781	CbGeAlD
Dinoprostone—CYP11A1—testis—muscle cancer	0.00102	0.00773	CbGeAlD
Dinoprostone—ABCC4—renal system—muscle cancer	0.00101	0.00766	CbGeAlD
Dinoprostone—SLC22A8—renal system—muscle cancer	0.001	0.0076	CbGeAlD
Dinoprostone—SLCO4A1—head—muscle cancer	0.00098	0.00744	CbGeAlD
Dinoprostone—Neck stiffness—Methotrexate—muscle cancer	0.000965	0.019	CcSEcCtD
Dinoprostone—SLCO4A1—testis—muscle cancer	0.000947	0.00718	CbGeAlD
Dinoprostone—ABCC5—testis—muscle cancer	0.000941	0.00714	CbGeAlD
Dinoprostone—PTGER4—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.000902	0.0227	CbGpPWpGaD
Dinoprostone—SLCO2B1—tendon—muscle cancer	0.00089	0.00675	CbGeAlD
Dinoprostone—Nuchal rigidity—Methotrexate—muscle cancer	0.000886	0.0174	CcSEcCtD
Dinoprostone—Chest discomfort—Etoposide—muscle cancer	0.000867	0.0171	CcSEcCtD
Dinoprostone—Skin discolouration—Etoposide—muscle cancer	0.000849	0.0167	CcSEcCtD
Dinoprostone—Inflammation—Etoposide—muscle cancer	0.000791	0.0156	CcSEcCtD
Dinoprostone—SLC22A1—vagina—muscle cancer	0.000789	0.00599	CbGeAlD
Dinoprostone—ABCC4—tendon—muscle cancer	0.000788	0.00598	CbGeAlD
Dinoprostone—Deafness—Vincristine—muscle cancer	0.000768	0.0151	CcSEcCtD
Dinoprostone—ABCC4—bone marrow—muscle cancer	0.000763	0.00579	CbGeAlD
Dinoprostone—SLCO2B1—head—muscle cancer	0.000763	0.00579	CbGeAlD
Dinoprostone—PTGER2—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.000741	0.0186	CbGpPWpGaD
Dinoprostone—SLCO2B1—testis—muscle cancer	0.000737	0.00559	CbGeAlD
Dinoprostone—SLC22A1—head—muscle cancer	0.000729	0.00553	CbGeAlD
Dinoprostone—SLCO1A2—head—muscle cancer	0.000702	0.00533	CbGeAlD
Dinoprostone—CYP1A2—renal system—muscle cancer	0.000686	0.0052	CbGeAlD
Dinoprostone—CYP19A1—head—muscle cancer	0.000685	0.0052	CbGeAlD
Dinoprostone—PTGER3—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.000684	0.0172	CbGpPWpGaD
Dinoprostone—SLCO1A2—testis—muscle cancer	0.000678	0.00514	CbGeAlD
Dinoprostone—ABCC4—head—muscle cancer	0.000675	0.00513	CbGeAlD
Dinoprostone—SLC22A8—head—muscle cancer	0.00067	0.00508	CbGeAlD
Dinoprostone—CYP19A1—testis—muscle cancer	0.000662	0.00502	CbGeAlD
Dinoprostone—Urinary retention—Vincristine—muscle cancer	0.000654	0.0129	CcSEcCtD
Dinoprostone—Cardiac arrest—Vincristine—muscle cancer	0.000654	0.0129	CcSEcCtD
Dinoprostone—ABCC4—testis—muscle cancer	0.000652	0.00495	CbGeAlD
Dinoprostone—Dehydration—Vincristine—muscle cancer	0.000639	0.0126	CcSEcCtD
Dinoprostone—HPGDS—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000605	0.0152	CbGpPWpGaD
Dinoprostone—HPGDS—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	0.00059	0.0149	CbGpPWpGaD
Dinoprostone—Anaphylactoid reaction—Etoposide—muscle cancer	0.000575	0.0113	CcSEcCtD
Dinoprostone—HPGDS—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000552	0.0139	CbGpPWpGaD
Dinoprostone—Laryngitis—Doxorubicin—muscle cancer	0.000552	0.0109	CcSEcCtD
Dinoprostone—ABCC4—Ectoderm Differentiation—PAX3—muscle cancer	0.00055	0.0138	CbGpPWpGaD
Dinoprostone—Cardiac arrest—Etoposide—muscle cancer	0.000529	0.0104	CcSEcCtD
Dinoprostone—Pharyngitis—Dactinomycin—muscle cancer	0.000528	0.0104	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Vincristine—muscle cancer	0.000522	0.0103	CcSEcCtD
Dinoprostone—Myocardial infarction—Vincristine—muscle cancer	0.000519	0.0102	CcSEcCtD
Dinoprostone—Musculoskeletal stiffness—Methotrexate—muscle cancer	0.000512	0.0101	CcSEcCtD
Dinoprostone—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.000511	0.0129	CbGpPWpGaD
Dinoprostone—Skin discolouration—Methotrexate—muscle cancer	0.000509	0.01	CcSEcCtD
Dinoprostone—Cramp muscle—Etoposide—muscle cancer	0.000501	0.00987	CcSEcCtD
Dinoprostone—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.0005	0.0126	CbGpPWpGaD
Dinoprostone—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.0005	0.0126	CbGpPWpGaD
Dinoprostone—Flushing—Dactinomycin—muscle cancer	0.000494	0.00972	CcSEcCtD
Dinoprostone—PTGFR—GPCRs, Other—CNR1—muscle cancer	0.000483	0.0122	CbGpPWpGaD
Dinoprostone—Chills—Dactinomycin—muscle cancer	0.000478	0.0094	CcSEcCtD
Dinoprostone—Inflammation—Methotrexate—muscle cancer	0.000474	0.00932	CcSEcCtD
Dinoprostone—Bronchospasm—Etoposide—muscle cancer	0.000473	0.00932	CcSEcCtD
Dinoprostone—CYP19A1—FSH signaling pathway—FOXO1—muscle cancer	0.00047	0.0118	CbGpPWpGaD
Dinoprostone—Sweating increased—Etoposide—muscle cancer	0.000469	0.00923	CcSEcCtD
Dinoprostone—HPGDS—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000465	0.0117	CbGpPWpGaD
Dinoprostone—Vaginal inflammation—Methotrexate—muscle cancer	0.000459	0.00904	CcSEcCtD
Dinoprostone—HPGDS—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000442	0.0111	CbGpPWpGaD
Dinoprostone—Skin discolouration—Doxorubicin—muscle cancer	0.00044	0.00867	CcSEcCtD
Dinoprostone—Vaginal infection—Methotrexate—muscle cancer	0.000434	0.00854	CcSEcCtD
Dinoprostone—Angiopathy—Vincristine—muscle cancer	0.000431	0.00849	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Etoposide—muscle cancer	0.000423	0.00832	CcSEcCtD
Dinoprostone—Myocardial infarction—Etoposide—muscle cancer	0.000421	0.00828	CcSEcCtD
Dinoprostone—Inflammation—Doxorubicin—muscle cancer	0.00041	0.00807	CcSEcCtD
Dinoprostone—Back pain—Vincristine—muscle cancer	0.0004	0.00788	CcSEcCtD
Dinoprostone—Vaginal inflammation—Doxorubicin—muscle cancer	0.000398	0.00783	CcSEcCtD
Dinoprostone—Hiccups—Doxorubicin—muscle cancer	0.000398	0.00783	CcSEcCtD
Dinoprostone—Myalgia—Dactinomycin—muscle cancer	0.000394	0.00776	CcSEcCtD
Dinoprostone—CYP11A1—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.000377	0.00948	CbGpPWpGaD
Dinoprostone—Vaginal infection—Doxorubicin—muscle cancer	0.000376	0.00739	CcSEcCtD
Dinoprostone—PTGER4—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000371	0.00932	CbGpPWpGaD
Dinoprostone—Cramps of lower extremities—Doxorubicin—muscle cancer	0.000365	0.00719	CcSEcCtD
Dinoprostone—Flushing—Etoposide—muscle cancer	0.000357	0.00704	CcSEcCtD
Dinoprostone—Hypertension—Vincristine—muscle cancer	0.000357	0.00703	CcSEcCtD
Dinoprostone—Myalgia—Vincristine—muscle cancer	0.000352	0.00694	CcSEcCtD
Dinoprostone—Angiopathy—Etoposide—muscle cancer	0.000349	0.00688	CcSEcCtD
Dinoprostone—ABCC4—Ectoderm Differentiation—DMD—muscle cancer	0.000349	0.00879	CbGpPWpGaD
Dinoprostone—Hypertonia—Doxorubicin—muscle cancer	0.000349	0.00686	CcSEcCtD
Dinoprostone—Immune system disorder—Etoposide—muscle cancer	0.000348	0.00685	CcSEcCtD
Dinoprostone—Chills—Etoposide—muscle cancer	0.000346	0.0068	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Methotrexate—muscle cancer	0.000345	0.00678	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000344	0.00678	CcSEcCtD
Dinoprostone—Anaphylactic shock—Vincristine—muscle cancer	0.000338	0.00665	CcSEcCtD
Dinoprostone—Hyperhidrosis—Vincristine—muscle cancer	0.000327	0.00643	CcSEcCtD
Dinoprostone—Back pain—Etoposide—muscle cancer	0.000324	0.00638	CcSEcCtD
Dinoprostone—Pain—Dactinomycin—muscle cancer	0.000323	0.00636	CcSEcCtD
Dinoprostone—Muscle spasms—Etoposide—muscle cancer	0.000322	0.00634	CcSEcCtD
Dinoprostone—Eye pain—Doxorubicin—muscle cancer	0.00032	0.0063	CcSEcCtD
Dinoprostone—PTGER4—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000318	0.00799	CbGpPWpGaD
Dinoprostone—Hypotension—Vincristine—muscle cancer	0.000316	0.00621	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000309	0.00608	CcSEcCtD
Dinoprostone—Hot flush—Doxorubicin—muscle cancer	0.000309	0.00608	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000308	0.00606	CcSEcCtD
Dinoprostone—Menopausal symptoms—Doxorubicin—muscle cancer	0.000306	0.00602	CcSEcCtD
Dinoprostone—PTGER2—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000304	0.00766	CbGpPWpGaD
Dinoprostone—Paraesthesia—Vincristine—muscle cancer	0.000303	0.00597	CcSEcCtD
Dinoprostone—PTGER3—G alpha (i) signalling events—CNR1—muscle cancer	0.000303	0.00761	CbGpPWpGaD
Dinoprostone—Body temperature increased—Dactinomycin—muscle cancer	0.000299	0.00588	CcSEcCtD
Dinoprostone—Abdominal pain—Dactinomycin—muscle cancer	0.000299	0.00588	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.000298	0.00587	CcSEcCtD
Dinoprostone—Loss of consciousness—Etoposide—muscle cancer	0.000295	0.0058	CcSEcCtD
Dinoprostone—Cough—Etoposide—muscle cancer	0.000293	0.00576	CcSEcCtD
Dinoprostone—Hypertension—Etoposide—muscle cancer	0.000289	0.0057	CcSEcCtD
Dinoprostone—Pain—Vincristine—muscle cancer	0.000289	0.00569	CcSEcCtD
Dinoprostone—Asthma—Methotrexate—muscle cancer	0.000288	0.00567	CcSEcCtD
Dinoprostone—PTGER4—GPCR ligand binding—PTCH1—muscle cancer	0.000286	0.00721	CbGpPWpGaD
Dinoprostone—Chest pain—Etoposide—muscle cancer	0.000285	0.00562	CcSEcCtD
Dinoprostone—PTGER3—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000281	0.00707	CbGpPWpGaD
Dinoprostone—Hypersensitivity—Dactinomycin—muscle cancer	0.000279	0.00548	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Vincristine—muscle cancer	0.000276	0.00544	CcSEcCtD
Dinoprostone—Cardiac arrest—Doxorubicin—muscle cancer	0.000275	0.0054	CcSEcCtD
Dinoprostone—Anaphylactic shock—Etoposide—muscle cancer	0.000274	0.00539	CcSEcCtD
Dinoprostone—Asthenia—Dactinomycin—muscle cancer	0.000271	0.00534	CcSEcCtD
Dinoprostone—Dehydration—Doxorubicin—muscle cancer	0.000269	0.00529	CcSEcCtD
Dinoprostone—Tachycardia—Etoposide—muscle cancer	0.000267	0.00526	CcSEcCtD
Dinoprostone—Abdominal pain—Vincristine—muscle cancer	0.000267	0.00526	CcSEcCtD
Dinoprostone—Body temperature increased—Vincristine—muscle cancer	0.000267	0.00526	CcSEcCtD
Dinoprostone—Hyperhidrosis—Etoposide—muscle cancer	0.000265	0.00521	CcSEcCtD
Dinoprostone—PTGER2—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000261	0.00656	CbGpPWpGaD
Dinoprostone—Diarrhoea—Dactinomycin—muscle cancer	0.000259	0.00509	CcSEcCtD
Dinoprostone—Hypotension—Etoposide—muscle cancer	0.000256	0.00503	CcSEcCtD
Dinoprostone—ABCC4—Platelet degranulation—IGF2—muscle cancer	0.000256	0.00643	CbGpPWpGaD
Dinoprostone—Asthma—Doxorubicin—muscle cancer	0.00025	0.00491	CcSEcCtD
Dinoprostone—Hypersensitivity—Vincristine—muscle cancer	0.000249	0.0049	CcSEcCtD
Dinoprostone—HPGDS—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000249	0.00626	CbGpPWpGaD
Dinoprostone—Paraesthesia—Etoposide—muscle cancer	0.000246	0.00484	CcSEcCtD
Dinoprostone—Dyspnoea—Etoposide—muscle cancer	0.000244	0.0048	CcSEcCtD
Dinoprostone—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	0.000244	0.00613	CbGpPWpGaD
Dinoprostone—Asthenia—Vincristine—muscle cancer	0.000242	0.00477	CcSEcCtD
Dinoprostone—PTGER4—GPCR ligand binding—CNR1—muscle cancer	0.000242	0.00608	CbGpPWpGaD
Dinoprostone—PTGER3—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000241	0.00605	CbGpPWpGaD
Dinoprostone—Vomiting—Dactinomycin—muscle cancer	0.00024	0.00473	CcSEcCtD
Dinoprostone—Rash—Dactinomycin—muscle cancer	0.000238	0.00469	CcSEcCtD
Dinoprostone—ABCC5—Fluoropyrimidine Activity—TP53—muscle cancer	0.000237	0.00597	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR ligand binding—PTCH1—muscle cancer	0.000235	0.00592	CbGpPWpGaD
Dinoprostone—Pain—Etoposide—muscle cancer	0.000234	0.00461	CcSEcCtD
Dinoprostone—Diarrhoea—Vincristine—muscle cancer	0.000231	0.00455	CcSEcCtD
Dinoprostone—Pharyngitis—Methotrexate—muscle cancer	0.000229	0.00451	CcSEcCtD
Dinoprostone—Nausea—Dactinomycin—muscle cancer	0.000225	0.00442	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Etoposide—muscle cancer	0.000224	0.0044	CcSEcCtD
Dinoprostone—Dizziness—Vincristine—muscle cancer	0.000223	0.0044	CcSEcCtD
Dinoprostone—PTGER4—Signaling Pathways—KIDINS220—muscle cancer	0.000221	0.00555	CbGpPWpGaD
Dinoprostone—ABCC5—Carbohydrate metabolism—ENO2—muscle cancer	0.00022	0.00554	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR ligand binding—PTCH1—muscle cancer	0.000217	0.00546	CbGpPWpGaD
Dinoprostone—Abdominal pain—Etoposide—muscle cancer	0.000216	0.00426	CcSEcCtD
Dinoprostone—Body temperature increased—Etoposide—muscle cancer	0.000216	0.00426	CcSEcCtD
Dinoprostone—Vomiting—Vincristine—muscle cancer	0.000215	0.00423	CcSEcCtD
Dinoprostone—Rash—Vincristine—muscle cancer	0.000213	0.00419	CcSEcCtD
Dinoprostone—Dermatitis—Vincristine—muscle cancer	0.000213	0.00419	CcSEcCtD
Dinoprostone—Headache—Vincristine—muscle cancer	0.000212	0.00416	CcSEcCtD
Dinoprostone—PTGFR—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.00021	0.00528	CbGpPWpGaD
Dinoprostone—Angiopathy—Methotrexate—muscle cancer	0.000209	0.00412	CcSEcCtD
Dinoprostone—Immune system disorder—Methotrexate—muscle cancer	0.000208	0.0041	CcSEcCtD
Dinoprostone—Chills—Methotrexate—muscle cancer	0.000207	0.00407	CcSEcCtD
Dinoprostone—PTGER1—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000206	0.00517	CbGpPWpGaD
Dinoprostone—PTGIR—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000206	0.00517	CbGpPWpGaD
Dinoprostone—SLC22A7—Fluoropyrimidine Activity—TP53—muscle cancer	0.000204	0.00514	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—ANGPT2—muscle cancer	0.000202	0.00507	CbGpPWpGaD
Dinoprostone—Hypersensitivity—Etoposide—muscle cancer	0.000202	0.00397	CcSEcCtD
Dinoprostone—Nausea—Vincristine—muscle cancer	0.000201	0.00395	CcSEcCtD
Dinoprostone—PTGER2—GPCR ligand binding—CNR1—muscle cancer	0.000199	0.005	CbGpPWpGaD
Dinoprostone—Pharyngitis—Doxorubicin—muscle cancer	0.000198	0.0039	CcSEcCtD
Dinoprostone—Asthenia—Etoposide—muscle cancer	0.000196	0.00386	CcSEcCtD
Dinoprostone—HPGDS—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000196	0.00493	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—FH—muscle cancer	0.000196	0.00493	CbGpPWpGaD
Dinoprostone—Back pain—Methotrexate—muscle cancer	0.000194	0.00382	CcSEcCtD
Dinoprostone—Vision blurred—Methotrexate—muscle cancer	0.000189	0.00373	CcSEcCtD
Dinoprostone—HPGDS—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000189	0.00476	CbGpPWpGaD
Dinoprostone—Diarrhoea—Etoposide—muscle cancer	0.000187	0.00368	CcSEcCtD
Dinoprostone—Flushing—Doxorubicin—muscle cancer	0.000185	0.00365	CcSEcCtD
Dinoprostone—CYP19A1—Tryptophan metabolism—MDM2—muscle cancer	0.000184	0.00463	CbGpPWpGaD
Dinoprostone—PTGER3—GPCR ligand binding—CNR1—muscle cancer	0.000183	0.00461	CbGpPWpGaD
Dinoprostone—Angiopathy—Doxorubicin—muscle cancer	0.000181	0.00357	CcSEcCtD
Dinoprostone—PTGER2—Signaling Pathways—KIDINS220—muscle cancer	0.000181	0.00456	CbGpPWpGaD
Dinoprostone—Dizziness—Etoposide—muscle cancer	0.000181	0.00356	CcSEcCtD
Dinoprostone—Immune system disorder—Doxorubicin—muscle cancer	0.00018	0.00355	CcSEcCtD
Dinoprostone—PTGFR—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.00018	0.00453	CbGpPWpGaD
Dinoprostone—Chills—Doxorubicin—muscle cancer	0.000179	0.00353	CcSEcCtD
Dinoprostone—Arrhythmia—Doxorubicin—muscle cancer	0.000178	0.00351	CcSEcCtD
Dinoprostone—PTGIR—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000176	0.00443	CbGpPWpGaD
Dinoprostone—PTGER1—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000176	0.00443	CbGpPWpGaD
Dinoprostone—Cough—Methotrexate—muscle cancer	0.000175	0.00345	CcSEcCtD
Dinoprostone—Vomiting—Etoposide—muscle cancer	0.000174	0.00342	CcSEcCtD
Dinoprostone—Rash—Etoposide—muscle cancer	0.000173	0.0034	CcSEcCtD
Dinoprostone—Dermatitis—Etoposide—muscle cancer	0.000172	0.00339	CcSEcCtD
Dinoprostone—Headache—Etoposide—muscle cancer	0.000171	0.00337	CcSEcCtD
Dinoprostone—Arthralgia—Methotrexate—muscle cancer	0.000171	0.00337	CcSEcCtD
Dinoprostone—Chest pain—Methotrexate—muscle cancer	0.000171	0.00337	CcSEcCtD
Dinoprostone—Myalgia—Methotrexate—muscle cancer	0.000171	0.00337	CcSEcCtD
Dinoprostone—Tension—Doxorubicin—muscle cancer	0.000171	0.00336	CcSEcCtD
Dinoprostone—Back pain—Doxorubicin—muscle cancer	0.000168	0.00331	CcSEcCtD
Dinoprostone—CYP1A2—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000168	0.00422	CbGpPWpGaD
Dinoprostone—Muscle spasms—Doxorubicin—muscle cancer	0.000167	0.00329	CcSEcCtD
Dinoprostone—PTGER3—Signaling Pathways—KIDINS220—muscle cancer	0.000167	0.00421	CbGpPWpGaD
Dinoprostone—ABCC4—Fluoropyrimidine Activity—TP53—muscle cancer	0.000164	0.00414	CbGpPWpGaD
Dinoprostone—Anaphylactic shock—Methotrexate—muscle cancer	0.000164	0.00323	CcSEcCtD
Dinoprostone—Vision blurred—Doxorubicin—muscle cancer	0.000164	0.00323	CcSEcCtD
Dinoprostone—Nausea—Etoposide—muscle cancer	0.000163	0.0032	CcSEcCtD
Dinoprostone—PTGFR—GPCR ligand binding—PTCH1—muscle cancer	0.000162	0.00408	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR ligand binding—PTCH1—muscle cancer	0.000159	0.004	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR ligand binding—PTCH1—muscle cancer	0.000159	0.004	CbGpPWpGaD
Dinoprostone—Hyperhidrosis—Methotrexate—muscle cancer	0.000158	0.00312	CcSEcCtD
Dinoprostone—Syncope—Doxorubicin—muscle cancer	0.000156	0.00307	CcSEcCtD
Dinoprostone—Hypotension—Methotrexate—muscle cancer	0.000153	0.00301	CcSEcCtD
Dinoprostone—Loss of consciousness—Doxorubicin—muscle cancer	0.000153	0.00301	CcSEcCtD
Dinoprostone—Cough—Doxorubicin—muscle cancer	0.000152	0.00299	CcSEcCtD
Dinoprostone—Hypertension—Doxorubicin—muscle cancer	0.00015	0.00295	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000149	0.00294	CcSEcCtD
Dinoprostone—HPGDS—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000149	0.00375	CbGpPWpGaD
Dinoprostone—Chest pain—Doxorubicin—muscle cancer	0.000148	0.00291	CcSEcCtD
Dinoprostone—Myalgia—Doxorubicin—muscle cancer	0.000148	0.00291	CcSEcCtD
Dinoprostone—Arthralgia—Doxorubicin—muscle cancer	0.000148	0.00291	CcSEcCtD
Dinoprostone—Paraesthesia—Methotrexate—muscle cancer	0.000147	0.0029	CcSEcCtD
Dinoprostone—PTGER4—Signaling by GPCR—PTCH1—muscle cancer	0.000147	0.0037	CbGpPWpGaD
Dinoprostone—Dyspnoea—Methotrexate—muscle cancer	0.000146	0.00288	CcSEcCtD
Dinoprostone—Anaphylactic shock—Doxorubicin—muscle cancer	0.000142	0.00279	CcSEcCtD
Dinoprostone—Pain—Methotrexate—muscle cancer	0.00014	0.00276	CcSEcCtD
Dinoprostone—Shock—Doxorubicin—muscle cancer	0.00014	0.00275	CcSEcCtD
Dinoprostone—Tachycardia—Doxorubicin—muscle cancer	0.000139	0.00273	CcSEcCtD
Dinoprostone—Hyperhidrosis—Doxorubicin—muscle cancer	0.000137	0.0027	CcSEcCtD
Dinoprostone—PTGFR—GPCR ligand binding—CNR1—muscle cancer	0.000137	0.00345	CbGpPWpGaD
Dinoprostone—PTGER4—GPCR downstream signaling—CNR1—muscle cancer	0.000137	0.00344	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR ligand binding—CNR1—muscle cancer	0.000134	0.00337	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR ligand binding—CNR1—muscle cancer	0.000134	0.00337	CbGpPWpGaD
Dinoprostone—Gastrointestinal pain—Methotrexate—muscle cancer	0.000134	0.00264	CcSEcCtD
Dinoprostone—Hypotension—Doxorubicin—muscle cancer	0.000133	0.00261	CcSEcCtD
Dinoprostone—Body temperature increased—Methotrexate—muscle cancer	0.00013	0.00255	CcSEcCtD
Dinoprostone—Abdominal pain—Methotrexate—muscle cancer	0.00013	0.00255	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000129	0.00254	CcSEcCtD
Dinoprostone—Paraesthesia—Doxorubicin—muscle cancer	0.000127	0.00251	CcSEcCtD
Dinoprostone—Dyspnoea—Doxorubicin—muscle cancer	0.000127	0.00249	CcSEcCtD
Dinoprostone—PTGFR—Signaling Pathways—KIDINS220—muscle cancer	0.000125	0.00315	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling by GPCR—CNR1—muscle cancer	0.000124	0.00312	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—KIDINS220—muscle cancer	0.000122	0.00308	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—KIDINS220—muscle cancer	0.000122	0.00308	CbGpPWpGaD
Dinoprostone—Pain—Doxorubicin—muscle cancer	0.000121	0.00239	CcSEcCtD
Dinoprostone—Hypersensitivity—Methotrexate—muscle cancer	0.000121	0.00238	CcSEcCtD
Dinoprostone—PTGER2—Signaling by GPCR—PTCH1—muscle cancer	0.000121	0.00304	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—ANGPT2—muscle cancer	0.00012	0.00302	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000118	0.00298	CbGpPWpGaD
Dinoprostone—Asthenia—Methotrexate—muscle cancer	0.000118	0.00231	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000116	0.00228	CcSEcCtD
Dinoprostone—ABCC4—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000113	0.00285	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000113	0.00284	CbGpPWpGaD
Dinoprostone—HPGDS—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000113	0.00283	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR downstream signaling—CNR1—muscle cancer	0.000112	0.00282	CbGpPWpGaD
Dinoprostone—Abdominal pain—Doxorubicin—muscle cancer	0.000112	0.00221	CcSEcCtD
Dinoprostone—Body temperature increased—Doxorubicin—muscle cancer	0.000112	0.00221	CcSEcCtD
Dinoprostone—Diarrhoea—Methotrexate—muscle cancer	0.000112	0.00221	CcSEcCtD
Dinoprostone—PTGER3—Signaling by GPCR—PTCH1—muscle cancer	0.000111	0.0028	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—MED12—muscle cancer	0.000111	0.00279	CbGpPWpGaD
Dinoprostone—Dizziness—Methotrexate—muscle cancer	0.000108	0.00213	CcSEcCtD
Dinoprostone—ABCC4—Platelet degranulation—VEGFA—muscle cancer	0.000107	0.0027	CbGpPWpGaD
Dinoprostone—Hypersensitivity—Doxorubicin—muscle cancer	0.000105	0.00206	CcSEcCtD
Dinoprostone—Vomiting—Methotrexate—muscle cancer	0.000104	0.00205	CcSEcCtD
Dinoprostone—PTGER3—GPCR downstream signaling—CNR1—muscle cancer	0.000104	0.00261	CbGpPWpGaD
Dinoprostone—Rash—Methotrexate—muscle cancer	0.000103	0.00203	CcSEcCtD
Dinoprostone—Dermatitis—Methotrexate—muscle cancer	0.000103	0.00203	CcSEcCtD
Dinoprostone—Headache—Methotrexate—muscle cancer	0.000103	0.00202	CcSEcCtD
Dinoprostone—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	0.000102	0.00257	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—CNR1—muscle cancer	0.000102	0.00256	CbGpPWpGaD
Dinoprostone—Asthenia—Doxorubicin—muscle cancer	0.000102	0.002	CcSEcCtD
Dinoprostone—ABCC5—Metabolism—FH—muscle cancer	0.000101	0.00255	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—ENO2—muscle cancer	0.000101	0.00254	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—IGF2—muscle cancer	9.81e-05	0.00247	CbGpPWpGaD
Dinoprostone—Nausea—Methotrexate—muscle cancer	9.74e-05	0.00192	CcSEcCtD
Dinoprostone—Diarrhoea—Doxorubicin—muscle cancer	9.71e-05	0.00191	CcSEcCtD
Dinoprostone—PTGER3—Signaling by GPCR—CNR1—muscle cancer	9.4e-05	0.00237	CbGpPWpGaD
Dinoprostone—Dizziness—Doxorubicin—muscle cancer	9.39e-05	0.00185	CcSEcCtD
Dinoprostone—Vomiting—Doxorubicin—muscle cancer	9.02e-05	0.00178	CcSEcCtD
Dinoprostone—Rash—Doxorubicin—muscle cancer	8.95e-05	0.00176	CcSEcCtD
Dinoprostone—Dermatitis—Doxorubicin—muscle cancer	8.94e-05	0.00176	CcSEcCtD
Dinoprostone—Headache—Doxorubicin—muscle cancer	8.89e-05	0.00175	CcSEcCtD
Dinoprostone—CYP11A1—Metabolism—FH—muscle cancer	8.88e-05	0.00224	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—PTCH1—muscle cancer	8.68e-05	0.00219	CbGpPWpGaD
Dinoprostone—Nausea—Doxorubicin—muscle cancer	8.43e-05	0.00166	CcSEcCtD
Dinoprostone—PTGFR—Signaling by GPCR—PTCH1—muscle cancer	8.33e-05	0.0021	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.26e-05	0.00208	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—PTCH1—muscle cancer	8.15e-05	0.00205	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—PTCH1—muscle cancer	8.15e-05	0.00205	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	7.89e-05	0.00199	CbGpPWpGaD
Dinoprostone—PTGFR—GPCR downstream signaling—CNR1—muscle cancer	7.74e-05	0.00195	CbGpPWpGaD
Dinoprostone—PTGIR—GPCR downstream signaling—CNR1—muscle cancer	7.58e-05	0.00191	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—CNR1—muscle cancer	7.58e-05	0.00191	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—FOXO4—muscle cancer	7.47e-05	0.00188	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	7.47e-05	0.00188	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—CNR1—muscle cancer	7.33e-05	0.00184	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—PTCH1—muscle cancer	7.13e-05	0.00179	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—MDM2—muscle cancer	7.11e-05	0.00179	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	7.07e-05	0.00178	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—CNR1—muscle cancer	7.03e-05	0.00177	CbGpPWpGaD
Dinoprostone—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	6.96e-05	0.00175	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—CNR1—muscle cancer	6.88e-05	0.00173	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—CNR1—muscle cancer	6.88e-05	0.00173	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	6.71e-05	0.00169	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—PTCH1—muscle cancer	6.58e-05	0.00166	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—FH—muscle cancer	6.51e-05	0.00164	CbGpPWpGaD
Dinoprostone—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	6.27e-05	0.00158	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—ENO2—muscle cancer	6.24e-05	0.00157	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—FOXO4—muscle cancer	6.13e-05	0.00154	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CNR1—muscle cancer	6.02e-05	0.00151	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—IGF2—muscle cancer	5.99e-05	0.00151	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—FH—muscle cancer	5.89e-05	0.00148	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—IGF2—muscle cancer	5.84e-05	0.00147	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—MED12—muscle cancer	5.73e-05	0.00144	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—HMGA1—muscle cancer	5.67e-05	0.00143	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—FOXO4—muscle cancer	5.66e-05	0.00142	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—FH—muscle cancer	5.57e-05	0.0014	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CNR1—muscle cancer	5.56e-05	0.0014	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—FOXO1—muscle cancer	5.52e-05	0.00139	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	5.4e-05	0.00136	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	5.28e-05	0.00133	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—ENO2—muscle cancer	5.23e-05	0.00131	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—FH—muscle cancer	5.1e-05	0.00128	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—FOXO4—muscle cancer	5.09e-05	0.00128	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—MED12—muscle cancer	5.02e-05	0.00126	CbGpPWpGaD
Dinoprostone—SLC22A2—Transmission across Chemical Synapses—MDM2—muscle cancer	4.92e-05	0.00124	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—IGF2—muscle cancer	4.92e-05	0.00124	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PTCH1—muscle cancer	4.92e-05	0.00124	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PTCH1—muscle cancer	4.82e-05	0.00121	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PTCH1—muscle cancer	4.82e-05	0.00121	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—FH—muscle cancer	4.76e-05	0.0012	CbGpPWpGaD
Dinoprostone—ABCC4—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	4.76e-05	0.0012	CbGpPWpGaD
Dinoprostone—SLC22A1—Transmission across Chemical Synapses—MDM2—muscle cancer	4.59e-05	0.00115	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—ENO2—muscle cancer	4.58e-05	0.00115	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—IGF2—muscle cancer	4.54e-05	0.00114	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—FOXO1—muscle cancer	4.53e-05	0.00114	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—FOXO4—muscle cancer	4.23e-05	0.00106	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—KIT—muscle cancer	4.2e-05	0.00106	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—FOXO1—muscle cancer	4.18e-05	0.00105	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CNR1—muscle cancer	4.15e-05	0.00105	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—FOXO4—muscle cancer	4.14e-05	0.00104	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—FOXO4—muscle cancer	4.14e-05	0.00104	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—VEGFA—muscle cancer	4.11e-05	0.00103	CbGpPWpGaD
Dinoprostone—CYP19A1—Integrated Breast Cancer Pathway—TP53—muscle cancer	4.08e-05	0.00103	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CNR1—muscle cancer	4.07e-05	0.00102	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CNR1—muscle cancer	4.07e-05	0.00102	CbGpPWpGaD
Dinoprostone—SLC22A2—Neuronal System—MDM2—muscle cancer	3.77e-05	0.000949	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—FOXO1—muscle cancer	3.76e-05	0.000945	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—MED12—muscle cancer	3.68e-05	0.000926	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.58e-05	0.000901	CbGpPWpGaD
Dinoprostone—HPGDS—Metabolism—PTGS2—muscle cancer	3.52e-05	0.000885	CbGpPWpGaD
Dinoprostone—SLC22A1—Neuronal System—MDM2—muscle cancer	3.52e-05	0.000885	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—KIT—muscle cancer	3.45e-05	0.000868	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—IGF2—muscle cancer	3.4e-05	0.000855	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—ENO2—muscle cancer	3.35e-05	0.000844	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—MED12—muscle cancer	3.33e-05	0.000837	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—IGF2—muscle cancer	3.32e-05	0.000836	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—IGF2—muscle cancer	3.32e-05	0.000836	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—MDM2—muscle cancer	3.31e-05	0.000833	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—KIT—muscle cancer	3.18e-05	0.000801	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—MED12—muscle cancer	3.15e-05	0.000792	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—FOXO1—muscle cancer	3.13e-05	0.000786	CbGpPWpGaD
Dinoprostone—PTGIR—Hemostasis—TP53—muscle cancer	3.11e-05	0.000782	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—FOXO1—muscle cancer	3.06e-05	0.00077	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—FOXO1—muscle cancer	3.06e-05	0.00077	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—ENO2—muscle cancer	3.03e-05	0.000763	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—MED12—muscle cancer	2.88e-05	0.000726	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—ENO2—muscle cancer	2.87e-05	0.000722	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—KIT—muscle cancer	2.86e-05	0.00072	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.82e-05	0.00071	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—MDM2—muscle cancer	2.72e-05	0.000684	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—MED12—muscle cancer	2.69e-05	0.000676	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—ENO2—muscle cancer	2.63e-05	0.000661	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.62e-05	0.00066	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—VEGFA—muscle cancer	2.51e-05	0.000632	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MDM2—muscle cancer	2.51e-05	0.000631	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—VEGFA—muscle cancer	2.45e-05	0.000617	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—ENO2—muscle cancer	2.45e-05	0.000617	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—KIT—muscle cancer	2.38e-05	0.000599	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.37e-05	0.000597	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—KIT—muscle cancer	2.33e-05	0.000587	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—KIT—muscle cancer	2.33e-05	0.000587	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—MDM2—muscle cancer	2.25e-05	0.000567	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.24e-05	0.000565	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—FH—muscle cancer	2.23e-05	0.00056	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—PTGS2—muscle cancer	2.17e-05	0.000547	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—VEGFA—muscle cancer	2.06e-05	0.000519	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—VEGFA—muscle cancer	1.9e-05	0.000479	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—TP53—muscle cancer	1.9e-05	0.000478	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MDM2—muscle cancer	1.88e-05	0.000472	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—TP53—muscle cancer	1.85e-05	0.000466	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MDM2—muscle cancer	1.84e-05	0.000462	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MDM2—muscle cancer	1.84e-05	0.000462	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PTGS2—muscle cancer	1.82e-05	0.000458	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PTGS2—muscle cancer	1.59e-05	0.000401	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—TP53—muscle cancer	1.56e-05	0.000392	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—TP53—muscle cancer	1.44e-05	0.000362	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—VEGFA—muscle cancer	1.42e-05	0.000358	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—VEGFA—muscle cancer	1.39e-05	0.000351	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—VEGFA—muscle cancer	1.39e-05	0.000351	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—MED12—muscle cancer	1.26e-05	0.000316	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PTGS2—muscle cancer	1.17e-05	0.000294	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—ENO2—muscle cancer	1.15e-05	0.000288	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TP53—muscle cancer	1.08e-05	0.000271	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PTGS2—muscle cancer	1.06e-05	0.000266	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—TP53—muscle cancer	1.05e-05	0.000265	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TP53—muscle cancer	1.05e-05	0.000265	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PTGS2—muscle cancer	9.99e-06	0.000251	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PTGS2—muscle cancer	9.16e-06	0.00023	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.97e-06	0.000226	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PTGS2—muscle cancer	8.53e-06	0.000215	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PTGS2—muscle cancer	3.99e-06	0.0001	CbGpPWpGaD
